Outcomes trials
Brief review previews CETP inhibitor trial results as REVEAL data for anacetrapib approaches (Eur Cardiol 2015)
Original title: Cholesteryl Ester Transfer Protein Inhibitors - Future Soon to be REVEALed
This brief review outlines the HDL hypothesis, the idea that raising plasma HDL cholesterol alongside lowering LDL cholesterol can address residual cardiovascular risk beyond statin therapy, and summarizes clinical results for the cholesteryl ester transfer protein (CETP) inhibitor drug class developed to raise HDL. The authors survey the family of CETP inhibitors and their trial history ahead of results from the phase III REVEAL trial testing anacetrapib, framing REVEAL as the pending test of whether CETP inhibition can translate into reduced cardiovascular events.
Original abstract
Reduction of the remaining residual cardiovascular risk is a clinical unmet need currently being addressed through a combination of further reduction of plasma concentrations of low-density lipoproteins (LDLs) and increasing plasma concentrations of high-density lipoproteins (HDLs). This brief review sets out the so-called HDL hypothesis and summarises the clinical results of the family of drugs, which function to raise plasma HDL concentration through inhibition of cholesteryl ester transfer proteins (CEPT).
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.